Biovica announces the appointment of Pontus Nobréus as Business Development Director, effective end of May 2018. Mr Nobréus has over 20 years’ experience working within the global sales, commercial and business development roles. Most recently, he was Global Sales Manager at Euro Diagnostica.
Biovica takes the next step in the process of commercializing DiviTum by launching a subsidiary in the United States.
Uppsala, Sweden, 2018-04-23, In accordance with the decision of the Annual General Meeting of Biovica International AB on August 31st, 2017, the Nomination Committee shall consist of three members, representing the two shareholders with the highest number of shares willing to be included in the Nomination Committee, and the Chairman of the Board. The Nomination Committee then elects the chairman.
Uppsala, Sweden, 2018-04-17, New results from a Pfizer study on Ibrance® (palbociclib, Pfizer) of women with metastatic breast cancer demonstrate that DiviTum can provide fast evaluation of biologic effect demonstrating CDK 4/6 inhibition.
Uppsala, Sweden, 2018-03-28 Results from a study of women with metastatic breast cancer demonstrate that DiviTum can provide faster evaluation of treatment efficacy than today’s standard methods and give precise prognosis.
Uppsala, Sweden 2018-03-20 Biovica has received an order for the company's DiviTum® product from a global diagnostic and contract research company (CRO company). DiviTum will be used during the development of a new targeted drug against cancer to study the effectiveness of the treatment.
Johns Hopkins University, Maryland, USA includes DiviTum® in a new study of metastatic breast cancer to study the development of resistance and efficacy of the new drug Ibrance® (palbociclib, Pfizer).
Uppsala, December 5, 2017. Biovica has appointed Adam Germunder as new Operations Manager. Adams responsibilities include to build and secure the company’s production capabilities and ensure that they meet regulatory requirements in preparation for the commercialization of DiviTum®.
Researchers at Washington University report: DiviTum® can evaluate the biologic activity of blockbuster breast cancer drug after two weeks
Uppsala, Sweden, November 23, 2017. Results of a study from Washington University, St Louis, demonstrate that the DiviTum® can evaluate the biologic activity of Pfizer’s breast cancer drug palbociclib (Ibrance®) in just two weeks are published in the latest edition of the scientific journal Breast Cancer Research and Treatment. This shortening of the response evaluation window can improve outcome and increase quality of life for breast cancer patients.
Uppsala, Sweden, November 21, 2017. In collaboration with University of Heidelberg, Germany, results from a clinical study of pancreatic cancer is published in the Pancreas scientific journal. The results demonstrate that Biovica’s DiviTum assay can provide an accurate prognosis and evaluation of treatment efficacy.